Key result
The purine-rich region of the Rous sarcoma virus negative regulator of splicing acts as an RNA splicing enhancer required for efficient splicing inhibition.
The purine-rich region of the Rous sarcoma virus NRS provides an RNA splicing enhancer function required for splicing inhibition, likely facilitating snRNP binding via SF2/ASF.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for retroviral splicing; requires validation in human models before any translational consideration.
The accumulation in infected cells of large amounts of unspliced viral RNA for use as mRNA and genomic RNA is a hallmark of retrovirus replication. The negative regulator of splicing (NRS) is a long cis-acting RNA element in Rous sarcoma virus that contributes to unspliced RNA accumulation through splicing inhibition. One of two critical sequences located in the NRS 3' region resembles a minor class 5' splice site and is required for U11 small nuclear ribonucleoprotein (snRNP) binding to the NRS. The second is a purine-rich region in the 5' half that interacts with the splicing factor SF2/ASF. In this study we investigated the possibility that this purine-rich region provides an RNA splicing enhancer function required for splicing inhibition. In vitro, the NRS acted as a potent, orientation-dependent enhancer of Drosophila doublesex pre-mRNA splicing, and enhancer activity mapped to the purine-rich domain. Analysis of a number of site-directed and deletion mutants indicated that enhancer activity was diffusely located throughout a 60-nucleotide area but only the activity associated with a short region previously shown to bind SF2/ASF correlated with efficient splicing inhibition. The significance of the enhancer activity to splicing inhibition was demonstrated by using chimeras in which two authentic enhancers (ASLV and FP) were substituted for the native NRS purine region. In each case, splicing inhibition in transfected cells was restored to levels approaching that observed for the NRS. The observation that a nonfunctional version of the FP enhancer (FPD) that does not bind SF2/ASF also fails to block splicing when paired with the NRS 3' region supports the notion that SF2/ASF binding to the NRS is relevant, but other SR proteins may substitute if an appropriate binding site is supplied. Our results are consistent with a role for the purine region in facilitated snRNP binding to the NRS via SF2/ASF.
No takes yet. Share an insight, caveat, or question.
McNally et al. (1998) studied Rous sarcoma virus infection. NRS purine-rich region vs. Mutant/deleted NRS regions was evaluated on Splicing inhibition. The purine-rich region of the Rous sarcoma virus negative regulator of splicing acts as an RNA splicing enhancer required for efficient splicing inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: